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CD40 is a potent activating receptor expressed on antigen-presenting cells (APCs) of the
immune system. CD40 regulates many aspects of B and T cell immunity via interaction
with CD40L expressed on activated T cells. Targeting antigens to CD40 via agonistic antiCD40 antibody fusions promotes both humoral and cellular immunity, but current antiCD40 antibody-antigen vaccine prototypes require co-adjuvant administration for
signiﬁcant in vivo efﬁcacy. This may be a consequence of dulling of anti-CD40 agonist
activity via antigen fusion. We previously demonstrated that direct fusion of CD40L to antiCD40 antibodies confers superagonist properties. Here we show that anti-CD40-CD40Lantigen fusion constructs retain strong agonist activity, particularly for activation of
dendritic cells (DCs). Therefore, we tested anti-CD40-CD40L antibody fused to
antigens for eliciting immune responses in vitro and in vivo. In PBMC cultures from HIV1-infected donors, anti-CD40-CD40L fused to HIV-1 antigens preferentially expanded
HIV-1-speciﬁc CD8+ T cells versus CD4+ T cells compared to analogous anti-CD40antigen constructs. In normal donors, anti-CD40-CD40L-mediated delivery of Inﬂuenza
M1 protein elicited M1-speciﬁc T cell expansion at lower doses compared to anti-CD40mediated delivery. Also, on human myeloid-derived dendritic cells, anti-CD40-CD40Lmelanoma gp100 peptide induced more sustained Class I antigen presentation compared
to anti-CD40-gp100 peptide. In human CD40 transgenic mice, anti-CD40-CD40L-HIV-1
gp140 administered without adjuvant elicited superior antibody responses compared to
anti-CD40-gp140 antigen without fused CD40L. In human CD40 mice, compared to the
anti-CD40 vehicle, anti-CD40-CD40L delivery of Ea 52-68 peptide elicited proliferating of
TCR I-Ea 52-68 CD4+ T cells producing cytokine IFNg. Also, compared to controls, only
anti-CD40-CD40L-Cyclin D1 vaccination of human CD40 mice reduced implanted
EO771.LMB breast tumor cell growth. These data demonstrate that human CD40CD40L antibody fused to antigens maintains highly agonistic activity and generates
immune responses distinct from existing low agonist anti-CD40 targeting formats.
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These advantages were in vitro skewing responses towards CD8+ T cells, increased
efﬁcacy at low doses, and longevity of MHC Class I peptide display; and in mouse models,
a more robust humoral response, more activated CD4+ T cells, and control of tumor
growth. Thus, the anti-CD40-CD40L format offers an alternate DC-targeting platform with
unique properties, including intrinsic adjuvant activity.
Keywords: dendritic cells, monoclonal antibodies, superagonist, adjuvant-intrinsic, vaccine

Pep-gag17-f1-gag253-f2-nef116-f3-nef66-f4-pol158) attached to
H chain C-termini has been detailed (7, 14) and is contained
within GenPept Sequence ID: AJD85777.1. The HPV16.E6/7 H
chain adduct (9) has been described (GenBank KP684039). The
Dockerin V1 (Doc) H chain adducts and Cohesin-Flu M1
protein were described elsewhere (6). Other antigen adducts
are described in the sections relevant to particular protocols.

INTRODUCTION
CD40 is a potent activating TNFR superfamily member expressed
on antigen-presenting cells (APCs) (1). Agonistic anti-CD40
monoclonal antibodies (mAbs) are in clinical development based
on the notion of directly activating APCs to stimulate immune
responses either against intrinsic antigens, e.g., tumor-associated
antigens (TAAs), or as an adjuvant to protein or peptide vaccines
(2–4). Directly linking antigens to anti-CD40 antibodies by
chemical conjugation (5), non-covalent assembly (6), or direct
fusion (7) elicits potent antigen-speciﬁc cellular and humoral
immunity at very low antigen doses in a wide array of in vitro and
in vivo settings (8–11). In particular, antigen-targeting to CD40
elicits superior cellular T cell responses compared to targeting other
specialized antigen-presenting Dendritic Cell (DC) receptors, likely
due to antigen accumulation within the early endosome
compartment, as distinct to the rapid antigen entry into late
endosomes characterized by targeting other DC receptors (8, 12).
Potent activation of CD40 is not required for efﬁcient Class I
and Class II presentation of antigens via CD40-targeting in vitro
(7, 12); however, in vivo efﬁcacy requires co-administration of
Toll-like receptor (TLR) activating agents such as poly IC (8–11).
Nonetheless, these in vitro and in vivo studies utilized anti-CD40
antibody-antigen complexes or fusions with low CD40 agonist
activity (7, 10), and the clear beneﬁt of agonistic anti-CD40
antibody combined with poly IC for peptide-based vaccination
in non-human primates (3) suggests CD40-targeting of antigens
may be further improved by utilizing fully agonistic anti-CD40
targeting vehicles.
In this study, we demonstrate that previously described
superagonist forms of anti-CD40 antibody generated by fusion to
CD40L (13) retain strong agonist activity when also linked to
various antigens. Our studies show that anti-CD40-CD40Lantigen constructs alter the nature of expanded antigen-speciﬁc
memory T cells in vitro, and in vivo can promote signiﬁcant cellular
and humoral responses without co-administered adjuvant, and thus
have potential as adjuvant-intrinsic DC-targeting vaccine vehicles.

B Cell Proliferation and DC Activation
B cell proliferation assays and DC activation assays were
performed as previously described (13). Brieﬂy, B cell assays
used CFSE-labeled human peripheral blood mononuclear cells
(PBMCs) incubated with a dose range of the test articles with
human IL-4 and human IL-21 for 5 days of culture, then cells
were stained with surface and live-dead markers followed by ﬂow
cytometry analysis gating on single live cells and CFSE−/CD19+
cells. To account for donor variation, independent experiments
were often collated by normalizing to the baseline and maximal
responses in each experiment. Typically, baseline percentages
across independent experiments using different donors were
consistently in the range of ~1 to ~10% for the antibodies
administered alone, and ~4 to ~22% for the antibodies
administered with the sCD40L. Maximum proliferation among
the experiments typically was in the range of ~46 to 97%. For DC
activation, myeloid-derived human dendritic cells (MDDC), from
human blood monocytes cultured with human IL-4 and human
GM-CSF for 5 days, were incubated with IL-4 and GM-CSF and a
dose range of the test articles. After 24 or 48 h, supernatants were
analyzed for secreted cytokines by Luminex®, and in some cases
the cells were stained for cell surface activation markers.

Surface Plasmon Resonance
SPR analyses were performed as previously described (13).

T Cell Expansion Assay
Cryopreserved human PBMC were thawed with 50 U/ml
benzonase® nuclease (Millipore, cat 70746), washed and rested
overnight in RPMI 1640 enriched with 100X PenStrep (Gibco,
15140-122), 100X Hepes Buffer (Gibco, 15630-080), 100X Nonessential amino acids (NEAA) (Gibco, 11140-050), 100X Sodium
Pyruvate (Gibco, 11360-070), 1000X 2-Mercaptoethanol (Gibco,
21985- 023), 100X Glutamax (Gibco, 35050-61) (herein called
complete RPMI 1640) with 10% AB serum (GemCell, 100-512) in
a 37°C 5% CO2 incubator. The following morning cells were ﬁltered
and cultured at a concentration of 2E6 cells/ml at 37°C in 1 ml
complete RPMI 1640 + 10% AB serum in a 24-well ﬂat bottom
plate. Cells were treated with different concentrations of anti-hCD40

MATERIAL AND METHODS
Anti-Human CD40 Monoclonal Antibodies
and Antigen Adducts
Sequences and production methods for in-house-derived 12E12,
11B6, 24A3, 12B4, and CP [CP-870,893, a Pﬁzer Inc. agonistic
antibody (4)] anti-human CD40 human IgG4 antibodies have
been described (13). The HIV-5pep antigen cassette (Flex-v1-

Frontiers in Immunology | www.frontiersin.org

2

January 2022 | Volume 12 | Article 786144

Ceglia et al.

Intrinsic Adjuvant Vaccines

antibodies or controls. After 48 h, 1 ml of complete RPMI 1640 with
10% AB serum and IL-2 (Proleukin, Sanoﬁ) at a ﬁnal concentration
of 100 U/ml was added to each well. Half of the media was changed
at day 4 and at day 6 adding fresh IL-2. At day 10, cells were
harvested and washed twice in PBS with 2 mM EDTA. Cells were
subsequently resuspended in complete RPMI 1640 + 10% AB serum
in 50 ml tubes, counted and rested overnight at 37°C. The day after,
cells were plated in a 96-well V-bottom plate in 200 µl volume per
well and restimulated with 2 mM peptides or controls for 1 h at
37°C. After 1 h, Golgi Stop (BD, 51-2092KZ) and Brefeldin A (BFA)
(BD, 420601) were added, and the cells were incubated for
additional 4 h. Subsequently, cells were washed, and surface and
intracellular staining was performed as described below in the
Intracellular Staining methods section, and gating was on singlets,
live cells, CD3+ followed by identiﬁcation of TNFa+ and IFNg+ in
both CD4+/CD8− and CD4−/CD8+ cells.

codons). ELISA plates were coated overnight at 4°C with 2 mg/ml
of the Cohesin fusion proteins in 0.2 M sodium carbonatebicarbonate buffer, pH 9.4. Serial dilutions of serum starting at
1:500 in TBS blocking solution (StartingBlock T20, Pierce or
Thermo Fisher Scientiﬁc) were incubated in the wells overnight
at 4°C. After washing, plates were incubated with HRP-conjugated
goat anti-mouse IgG (Jackson ImmunoResearch, West Grove, PA,
USA) in TBS blocking solution (Thermo Scientiﬁc, Rockford, IL,
USA) for 2 h at 37°C, then washed and developed with HRP
substrate (TMB, Life Technologies), stopped with equal volume of
1N HCl and read at 450 nm. The log10 transformed and
normalized areas under the curves (AUC) data were calculated
for each animal at each time point using GraphPad Prism 8
software. EC50 calculations were based on log10 transformed and
normalized data with non-linear regression curve ﬁt using
sigmoidal dose response with variable slope constraints.

Melanoma gp100 Peptide
Presentation Studies

Adoptive T Cell Transfer
CD4+ T cells speciﬁc to the Ea peptide bound to class II
I-Ab were adoptively transferred, as previously described (17).
Brieﬂy, six skin-draining lymph nodes (LNs), spleens, and
mesenteric LNs of TEa TCR transgenic mice were disrupted
through a 40 µm cell strainer, washed with sterile Hanks’
Balanced Salt Solution (HBSS), and labeled with cell trace
violet (CTV; Thermo Fisher Scientiﬁc), according to the
manufacturer’s instructions. The cells were resuspended in
sterile PBS at a concentration of 1E6 cells/ml, and 300 µl (3E5
cells) were injected intravenously into human CD40 mice
(Taconic) (13). Twenty-four hours later, mice were injected
intraperitoneally with 1 µg of anti-hCD40 11B6 non-covalently
linked to Ea protein or 1 µg of anti-hCD40 11B6-CD40L noncovalently linked to Ea protein, and skin-draining LNs were
harvested 4 days later. Cell suspensions were stimulated in
complete RPMI 1640 with PMA (Sigma) (5 ng/ml) and
Ionomycin (Sigma) (500 ng/ml) for 5 h. BFA (Biolegend) was
added to the cell suspension 1 h after the beginning of the
incubation. After stimulation, cells were washed and stained for
surface markers as described below in the Surface Staining for
Flow Cytometry Analysis methods section. Intracellular cytokine
staining was performed with the BD Bioscience Cytoﬁx/
Cytoperm kit (BD Biosciences, San Jose, CA, USA), according
to the manufacturer’s instructions and as described below. The
Ea antigen was contained within 6xHis-Cohesin-TEa-Flexv1C3 protein, which was expressed in E. coli as 6xHis-Cohesin
(Sequence ID: ALO70206.1) fused at the C-terminus to residues
52–68 (ASFEAQGALANIAVD) of the I-Ea chain (Ea peptide),
followed by KAGGASCQTPTNTISCTPTNNSNPKPCPAS.

To detect processing and presentation of the melanoma gp100
Class I peptide gp100 209-217 in the context of cell surface HLAA2, we used the TCR-like 1A9 mAb (15) H and L chain sequences
from patent US20030223994A1 fused to a human IgG4 H chain
with a C-terminal Dockerin V1 domain (6) and human L k chain
framework conjugated to either a Cohesin domain fused to a Cterminal CLIP tag (Sequence ID: AQS79240.1 residues 1–182 with
appended GEPA) labeled with CLIP-647 according to the
manufacturer’s protocol (NEB S9234), or a Cohesin-eGFP fusion
protein (LDITH6 residues fused to a Cohesin domain from
cellulosomal-scaffolding [Hungateiclostridium thermocellum]
WP_065674352.1 residues 1044-1213 with a f1 ﬂexible linker
AVY25163.1 residues 580–608 to ABF13214.1 eGFP residues
123–361 followed by a EPEA sequence used for C-tag afﬁnity
matrix CaptureSelect™ [Thermo Fisher, 191307005]), or a Alexa
Fluor® 546 C5 Maleimide (ThermoFisher A10258) fused to
Cohesin-SH (Sequence ID: ALO70206.1 residues 1–195 with a
C61A replacement and CG appended) through maleimide
reaction. The speciﬁcity of this antibody conjugate was
conﬁrmed by loading gp100 peptides (gp100 G9 Short [NH2]
IMDQVPFSV[COOH] or gp100 G9 Long [NH2]
CSSSKRIMDQVPFSV[COOH]) at 100 mM onto the human
CD40 + HLA class-I A2 + lymphoblastoid JY cell line
(ECACC® 94022533-1VL) for 24 h and comparing, via ﬂow
cytometry, binding to loaded cells versus non-loaded cells
(Supplemental Figure 1A). To deliver the peptide via DCtargeting, anti-hCD40-IgG4 mAbs were fused via the H-chain Cterminus to two copies of the short peptide interspersed between
ﬂexible linker sequences (7). A non-DC reactive hIgG4 mAb fused
to the same gp100 peptide cassette was used as a non-targeting
control. The gating strategy for ﬂow cytometry analyses is
described in Supplemental Figure 1B.

Cyclin D1 Tumor Curative Test
One million TNBC EO771.LMB Cyclin D1-expressing tumor
cells (18) suspended in 20 ml sterile PBS were injected into the
mammary fat pad of 10 to 15 weeks old female, human CD40
transgenic mice (Taconic). The mice were monitored daily by
measuring tumor size with a caliper. At days 7, 17, and 24, mice
were injected with 20 mg of anti-hCD40 (clone 11B6), antihCD40-CD40L (11B6-CD40L), IgG4 or IgG4-CD40L noncovalently linked to either Cyclin D1 constructs p1 or p2-4.

ELISA
Cohesin fusion proteins were expressed in CHO-S cells from
expression vectors containing the HIV-1 Env gp140 sequence (16)
or Env fragments (gp120 residues 94–1550; gp41 residues 1551–
2064, inserted between the Cohesin domain and 6 C-terminal His
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The 20 mg dose was administered via injections of 10 mg vaccine,
one to deliver p1 and the other to deliver p2-4. A group of mice
was left unimmunized. On day 28, the mice were euthanized, and
the tumors’ weight determined using an analytical scale. One
Cohesin-human Cyclin D1 fusion protein was 6xHisCthermoCohesin-Flex-v1-hCyclin D1-Peptide-1-f4-Ctag, which
has a N-terminal Cyclin D1 segment (sequence ID: AAA36481.1
residues 1-48) appended onto the C-terminal Nhe I site of the
His-tagged Cohesin coding sequence (6) followed by a ﬂexible
linker f4 (sequence ID: AJD85777.1 residues 697-793)
terminating in EPEA, and was expressed in CHO-S cells and
puriﬁed by C-tag afﬁnity as described above. A second Cohesinhuman Cyclin D1 fusion protein was 6xHis-CthermoCohesinFlex-v1-hCyclin D1-Peptide-2-Peptide-3-Peptide-4-f4-Ctag,
which has a Flex V1 sequence (Sequence ID: ALO70201.1
residues 466–496) appended onto the C-terminal Nhe/I site of
the His-tagged Cohesin coding sequence (6) followed by the
additional Cycln D1 segment (Sequence ID: NP_444284.1
residues 49–295) followed by a ﬂexible linker f4 (Sequence ID:
AJD85777.1 residues 697–793) terminating in EPEA, and was
expressed and puriﬁed as described above.

hCD14-PE, clone 61D3, ref 12-0149-42, (Thermo Fisher), or
hCD14-FITC, clone M5E2, ref 301804 (Biolegend), hCD56-PE,
clone B159, ref 555516 (BD) or hCD56-FITC, clone HCD56, ref
318304 (Biolegend), hCD66b-PE, clone G10F5, ref 561650 (BD)
or hCD66b-FITC, clone G10F5, ref 305104 (Biolegend). hCD19APC, clone HIB19, ref 555415 (BD) and hCD3-PerCP, clone
SK7, ref 347344 (BD) were used in the human B cell proliferation
panel. The following reagents were used for the adoptive T cell
transfer assay: CD90.1-PerCPCy5.5 (BioLegend 202516), IFNgPECy7 (Tonbo Biosciences 60-7311-U100), and CD4-BV711
(BioLegend 100447). The T cell proliferation panel was as
follows: hCD3-BV711, clone UCHT1, ref 563725 (BD) or
hCD3-PerCP clone SK7, ref 347344 (BD), hCD4-Pe-Cy7 clone
SK3, ref 348789 (BD), hCD8-PacBlue clone 3B5, ref MHCD0828
(Invitrogen), hTNFa-APC clone RUO, ref 340534 (BD), and
hIFNg-PE clone RUO, ref 340452 (BD).

Intracellular Staining
Human cells were stained for surface markers as described above.
After 30 min incubation on ice with the antibodies for surface
staining, cells were washed in PBS twice and resuspended in BD
Cytoﬁx/Cytoperm (BD Biosciences, 554714) for 20 min at 4°C,
followed by three washes in 1X BD Permwash (BD Biosciences,
554714). Cells were subsequently incubated at room temperature
covered by light in 1X BD Permwash with the antibody mix for
intracellular cytokines. Following the incubation time, cells were
washed three times in 1X BD Permwash and resuspended in BD™
stabilizing ﬁxative diluted 1:3. Mouse cells were stained for surface
markers as described above. After the incubation time, cells were
washed with Staining Buffer and resuspended overnight with the
mix of antibodies. Subsequently, cells were washed in BD
Permwash, resuspended in BD Permwash, and analyzed. All
analysis plots were pre-gated on singlet events and live. Cells
were analyzed with a FACS Canto II or an LSR Fortessa (BD
Biosciences). Data were analyzed with FlowJo® Software.

Surface Staining for Flow
Cytometry Analysis
Cells were transferred to a 96-well V-bottom plate, washed twice
in PBS, and incubated for 20 min at 4°C with Live/Dead™
Fixable Aqua Dead Cell Stain Kit (Thermo Fisher Scientiﬁc, Cat.
L34965) or with Live/Dead-ef780 (Thermo Fisher Scientiﬁc 650865-14) following the manufacturer’s instructions. Cells were
washed twice with PBS and incubated for 30 min on ice with the
mix of antibodies in a volume of 50 ml. Finally, cells were washed
and resuspended in 200 ml BD™ stabilizing ﬁxative (BD
Biosciences, Cat. 338036) per manufacturer’s instructions.
Alternatively, cells were resuspended in a volume of 100 ml of
Staining Buffer (PBS + 3% Bovine Serum + 5mM EDTA) in a Ubottom plate in the presence of Live/Dead-ef780 and the mix of
antibodies for 30 min on ice. Cells were subsequently washed and
resuspended in Staining Buffer before being analyzed. All
analysis plots were pre-gated on singlet events and live. Cells
were analyzed with a FACSCanto II or an LSRFortessa (BD
Biosciences). Data was analyzed with FlowJo ® Software
(TreeStar; Ashland, OR, USA).
The following antibodies were used for analysis of human DC
activation: hCD80-PE, clone L307.4, ref 340294 (BD), hCD83APC, clone HB15e, ref 551073 (BD); hCD86-FITC, clone 2331
(FUN-1), ref 555657 (BD); hCD11c-PE-Cyanine7, clone 3.9, ref
25011642, (eBioscience); hHLA-DR-V450, clone G46-6, ref
561359 (BD); hCD40-PE-Cyanine5, clone 5C3, ref 555590
(BD). The following panel was used in the melanoma gp100
peptide presentation assays: hCD83-BV421, clone HB15e, ref
562630 (BD); hCD86-Pe-Cy5, clone IT2.2, ref 555666 (BD);
hCD11c-APC-Cyanine7, clone Bu15, ref 337218, (Biolegend);
hHLA-DR-BV711, clone G46-6, ref 563696 (BD); hCD40-PE,
clone 5C3, ref 555589 (BD) (used when the panel allowed it),
hCD3-PE, clone SP34-2, ref 552127 (BD) or hCD3-FITC, clone
HIT3a (RUO), ref 555339 (BD), hCD19-PE, clone HIB-19, ref
561741 (BD), or hCD19-FITC, clone 4G7, ref 347543 (BD),
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Mouse Experiments
Human CD40 transgenic mice have the human CD40 region
BAC inserted into a wild type C57BL/6 background [Taconic
strain 12692 (13)]. CD90.1 congenic TEa Rag1−/− CD4 TCR
transgenic mice to I-Ea52−68 on the C57BL/6 background were
obtained from M. Jenkins (University of Minnesota). All
experiments were performed with 6- to 12-week-old female
and male mice. Mice were housed in micro-isolator cages and
fed irradiated food and acidiﬁed water. The Baylor Scott and
White Research Institute and South Dallas Veteran’s
Administration Institutional Care and Use Committees
approved all mouse protocols.

Statistical Analyses
Data are presented as means ( ± SEM). Statistical signiﬁcance
was determined by Student’s t test with or without Welch’s
correction. A P value < 0.05 was considered as statistically
signiﬁcant. GraphPad Prism® software was used for statistical
calculations. The following nomenclature was used in ﬁgures to
indicate the statistical signiﬁcance: * P 0.01 to 0.05; ** P 0.001 to
0.01; *** P 0.0001 to 0.001; **** is P< 0.0001.
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12B4 and anti-CD40 12E12 antibodies, but the low 6 nM dose of
sCD40L greatly increased the potency and efﬁcacy of the anti-CD40
11B6 and CP antibodies (Figure 1D). As observed with B cell
proliferation, suboptimal level of sCD40L also potentiated the
activity on MDDCs of the anti-CD40 11B6-HIV5pep and antiCD40 CP-HIV5pep fusion proteins, but had no effect at the tested
doses on the anti-CD40 12B4-HIV5pep or anti-CD40 12E12HIV5pep fusion proteins (Figure 1D). Overall, the extent of
sCD40L potentiation at the sCD40L concentration tested was ~5to 10-fold less with the anti-CD40-HIV5pep fusion proteins than
that observed with the anti-CD40 11B6 and CP non-antigen fused
mAbs (Figure 1D).
Unlike in the B cell proliferation assay, a large increase in efﬁcacy
(i.e., maximal activation marker increase achieved) between
antibody alone and antibody with sCD40L was observed,
indicating a greater potential for co-operation between these two
CD40 agonist types on MDDCs. This effect was also seen with
potentiation of cytokine secretion by non-antigen fused anti-CD40
11B6 and CP antibodies when combined with sCD40L (13).

RESULTS
Fusing Various Antigens to Agonistic AntiCD40 mAbs Can Dull CD40 Activation
Efﬁcacy, but Some Anti-CD40 mAbAntigen Fusions Synergize With sCD40L
to Restore CD40 Activation Potency
Fusion of antigens to the C-terminus of chimeric or humanized
anti-CD40 agonistic antibodies can dull or eliminate the agonistic
property of the parent antibody (7). We generated a panel of
agonistic anti-CD40 antibodies conﬁgured on human IgG4
isotypes, with or without a concatenated string of HIV-1 long T
cell epitope-rich peptides from the Gag, Nef, and Pol gene regions
grafted to their H chain C-termini (7). It is known that antibody
isotype can impact CD40 agonistic potency via FcRg interaction
(2); thus, the human IgG4 isotype was selected since it has low
binding to FcRg (19), allowing a clear interpretation that the
agonistic and antigen-presenting properties of our tested panel of
anti-CD40-antigen fusion mAbs was due exclusively to CD40
interaction. As we described previously (13), the four selected
parental mAbs, all with their variable regions conﬁgured as human
IgG4 H chain and human K L chain constant regions, varied in
their potency for evoking human B cell proliferation over a 100fold range of agonist efﬁcacies (Figure 1A) with rank order
CP>12B4≥12E12>11B6 [CP is Pﬁzer CP-870,893, an agonist
anti-CD40 human IgG2 antibody in clinical development, here
re-conﬁgured as a human IgG4 antibody (20)]. In all cases, the
agonist activity was severely decreased (>10–100-fold) when the
mAb C-terminus was fused to ﬁve concatenated HIV-1 long
peptide regions interspersed with glycosylated ﬂexible linkers
(HIV5pep antigen cassette) (Figure 1A). We also previously
showed that the anti-CD40 11B6 and CP mAbs, which do not
signiﬁcantly block CD40L interaction with CD40, synergize
strongly with soluble CD40L (13) (Figure 1B). The agonistic
anti-CD40 11B6, 12B4, 12E12, and CP hIgG4 mAbs all became
very weak agonists for eliciting B cell proliferation when the
HIV5pep antigen cassette was grafted to their H chain Ctermini (Figure 1A). Addition of suboptimal levels of
monomeric sCD40L restored the B cell proliferation potency of
the anti-CD40 11B6-HIV5pep and anti-CD40 CP-HIV5pep
mAbs to the level characteristic of the analogous “naked” antiCD40 11B6 and CP mAbs incubated with sCD40L, but had no
signiﬁcant effect on the anti-CD40 12B4-HIV5pep or anti-CD40
12E12-HIV5pep mAbs (Figure 1B).
Since dendritic cells (DCs) are the desired target cells for
delivering antigens for potent vaccination responses, we
examined these same four agonist anti-CD40-HIV5pep fusion
proteins for potency of upregulation of activation markers on
human myeloid-derived dendritic cells (MDDCs). As previously
described (13) and as observed with the B cell proliferation assay
(Figures 1A, B), the non-fusion antibody panel had minimal
efﬁcacy at the 10–0.1 nM concentrations tested compared to the
more sensitive B cell proliferative response (Figure 1C). However,
as previously observed (13), when assayed over this dose range
together with a suboptimal dose of soluble monomeric CD40L
(sCD40L), there was no effect on the dose response of the anti-CD40
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Agonistic Properties of Anti-CD40 mAbs
Dulled by Antigen Fusion Can Be Restored
via Direct Fusion of CD40L to Their Light
Chain C-Termini
We have shown that direct fusion of CD40L to agonistic antiCD40 mAbs stabilizes binding to CD40 and thus potentiates
their agonist activities, emulating or surpassing the synergism
seen with co-administered sCD40L (13). While previous
prototypes of anti-CD40-HIV5pep vaccines were based on the
humanized 12E12 mAb (14, 21), we focused on the anti-CD40
11B6 mAb since it shows the strongest cooperation with soluble
CD40L for agonist activity (Figures 1B, D) (13). Similarly to
what we previously observed (13), using Surface Plasmon
Resonance analyses with solid phase CD40 ectodomain to test
the binding kinetic properties of our anti-CD40 constructs,
direct fusion of CD40L to the anti-CD40 12E12 did not
improve the afﬁnity of this antibody, likely due to the fact that
the anti-CD40 12E12 binding site interferes with CD40L
binding, but in contrast, CD40L fusion greatly improves the
afﬁnity via stabilizing off-rate of the anti-CD40 11B6 antibody,
which binds CD40 without blocking CD40L access (Figure 2A)
(13). The direct fusion of the HIV5pep adduct on both the antiCD40 12E12 and on the anti-CD40 11B6 slightly reduced the
afﬁnity of both antibodies by ~66% and ~50% respectively, likely
due to changes in diffusion from increased bulk. However, direct
fusion of CD40L to the anti-CD40 11B6-HIV5pep construct
maintained the greatly increased afﬁnity to CD40 observed with
anti-CD40 11B6-CD40L without fused antigen, while anti-CD40
12E12-HIV5pep did not improve afﬁnity to CD40 after direct
fusion to CD40L (Figure 2A). These data conﬁrm that the direct
fusion of CD40L on anti-CD40 11B6, either with or without an
antigen attached, improves the afﬁnity of the antibody for CD40.
Thus, we asked if the improved binding to CD40 by antiCD40 11B6-CD40L HIV5pep fusion protein could mirror the
restoration of high agonist activity we observed by adding soluble
CD40L. In B cell proliferation assays, anti-CD40 11B6-HIV5pep
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FIGURE 1 | Response of human B cells and human MDDCs to a dose range of anti-CD40 mAbs and matched anti-CD40 HIV5pep antigen fusion proteins
incubated with and without a constant low dose of soluble CD40L. (A) shows responses to dose ranges (shown left to right: 10, 1, 0.1 nM for the three point
titrations, and 10, 1, 0.1, 0.01 nM for the four point titrations) in six collated independent experiments to the indicated anti-CD40 or control hIgG4 antibodies or of
one experiment with the same anti-CD40 hIgG4 or control hIgG4 antibody fused to the HIV5pep antigen. (B) shows response of four collated independent
experiments to doses (shown left to right: 10, 1, 0.1 nM for the three point titrations, and 10, 1, 0.1, 0.01 nM for the four point titrations) of the same anti-CD40 or
control antibodies and one independent experiment with matching HIV5pep fusion proteins in the presence of 100 ng/ml (6 nM) monomeric soluble human CD40L.
The data were normalized to the maximum B cell proliferation observed in each experiment. (C, D) show DC activation responses to a dose range (shown left to
right: 10, 1, 0.1 nM) of each indicated anti-CD40 hIgG4 mAb and matching anti-CD40-HIV5pep fusion protein antibodies in the absence (C) or presence of 100 ng/
ml (6 nM) soluble human CD40L (D). The percentage of cells with high expression of CD86 and DR determined by ﬂow cytometry is shown. Data are from a single
representative experiment. We have previously shown analogous data for the indicated non-fusion antibodies with or without sCD40L (13), and these data are
included for reference. The control hIgG4 antibody we used does not bind to human monocytes, B cells, or MDDCs (7).

mAb, but CD40L L chain fusion potentiated the activation to levels
equal to the mAbs co-administered sCD40 (Figure 3A). The
increase on B cell proliferation activity was mirrored by robust
cytokine production from MDDC elicited by anti-CD40 11B6GNG (Figures 3B, C). Altogether, these data demonstrate the
superagonist properties of anti-CD40 11B6-CD40L on B cells
and DCs are maintained when fused to the three tested antigen
modules—HIV5pep, GNG, and HPV16 E6/E7.

had minimal agonist activity; however, both anti-CD40 11B6HIV5pep + sCD40L and anti-CD40 11B6-CD40L-HIV5pep had
high agonist activity that approached that of the superagonist
anti-CD40 11B6-CD40L (Figure 2B). This indicates that direct
fusion of CD40L can render a weak agonist anti-CD40-HIV5pep
fusion construct into a strong agonist. Anti-CD40 11B6-CD40LHIV5pep constructs also had potent agonist activity on DCs
(Figures 2C–E), exceeding the activity of the naked anti-CD40
CP agonist hIgG4 mAb or the highly active Mega sCD40 trimer
(22). Thus, the observed increase in CD40 binding by the antiCD40 11B6-CD40L-HIV5pep protein is associated with highly
increased activity on B cells and DCs.
To test if CD40L fusion to anti-CD40 IgG4 L chain C-termini
could also increase agonist potency while fused to other desirable
antigens, we compared agonistic activities when anti-CD40 11B6
and 12E12 IgG4 mAbs were fused at their H chain C-termini to
concatenated HIV-1 Gag p24 Nef Gag p17 (called GNG) or HPV16
E6/E7 (called HPV) antigens (9), with or without CD40L directly
fused to the L chain. These two antigens do not signiﬁcantly dull the
already low potency of B cell CD40 activation of the parent 11B6

Frontiers in Immunology | www.frontiersin.org

Anti-CD40-CD40L-Antigen Fusion
Vaccines Preferentially Expand AntigenSpeciﬁc Memory CD8+ T Cells In Vitro
Peripheral Blood Mononuclear Cell (PBMC) and DC-T cell coculture systems are useful in in vitro assays for validating DCtargeting prototype vaccine constructs, in particular for selecting
the best DC receptor to target, e.g., for cellular T cell response (8),
as well as conﬁrming the efﬁcacy of the selected fused antigen for
eliciting a broad range of T cell peptide speciﬁcities for both CD4+
and CD8+ T cell recall responses across a range of HLA types (7).
To investigate the potential impact of associating antigen delivery
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FIGURE 2 | Direct fusion of CD40L to anti-CD40 antibody-antigen fusion protein improves afﬁnity for CD40 binding and confers high agonist activity on human B cells
and MDDCs. (A) Shows surface plasmon resonance analyses for anti-CD40 11B6 (top panels) and anti-CD40 12E12 (bottom panels), with or without directly fused
CD40L and/or with or without the HIV5pep adduct. (B) Shows B cell proliferation in response to a dose range (left to right, 10, 1, 0.1, 0.01 nM) of the indicated antiCD40 11B6 hIgG4 antibodies or antibody-HIV5pep fusions with added 60 nM sCD40L, or with CD40L directly fused to the antibody L chain C-termini. Data represent
averaged values for two donors each normalized for maximum proliferation. (C–E) Shows DC activation to a dose range (left to right, 10, 1, 0.1, 0.01 nM) of each
indicated IgG4 mAb or Mega sCD40L (a trimeric form of sCD40L, EnzoLifeScience, ref ALX-522-110-C010) based on the extent of cytokine secretion determined at
24 h. The results presented are averaged data over three experiments using two different donors. Panels (C–E) show, respectively, the averaged IL-12 p40, TNFa, and
IL-15 secretion. The error bars are standard deviation of the mean. Supplemental Table 1 summarizes the relative efﬁcacies of this cytokine secretion data.

terminus. PBMCs from the donor shown in Figure 4 treated
with a dose ≥0.01 nM of CD40-targeting GNG constructs
expanded memory CD4+ T cells speciﬁc to epitopes within all
three Gag p17, Nef, and Gag p24 regions, while such cells were
minimally represented in antigen non-stimulated or non-targeting

with potent CD40 activation, we ﬁrst evaluated the efﬁcacy for
HIV-1 antigen-speciﬁc T cell expansion in HIV-1+ donor PBMC
cultures of anti-CD40 mAbs fused at the C-termini to a Gag p17Nef-Gag p24 (GNG) antigen cassette, with and without a low dose
of sCD40L or with CD40L directly fused to the L chain C-
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FIGURE 3 | Anti-CD40 11B6-CD40L fused to HIV-1 Gag p24, Nef, and Gag p17 or HPV16 E6/E7 antigens is highly active on human B cells and DCs. (A) Shows B cell
proliferation in response to a dose range (shown left to right: 10, 1, 0.1, 0.01 nM) of the indicated antibody or antibody-antigen fusion protein; curves with gray ﬁlled
square symbols are responses doses to the indicated antibody or anti-CD40 11B6-antigen fusion protein in the presence of 1 mg/ml (60 nM) soluble human CD40L or
fused directly to CD40L. Data represent a single experiment normalized for maximum proliferation (95%) versus baseline proliferation without antibody (10%). (B, C) show
MDDC cytokine secretion responses to a dose range (shown left to right: 10, 1, 0.1 nM) of each indicated mAb. Data show observed concentration values in pg/ml. The
maximal values were IL-12p40, 359 ng/ml; TNFa, 6134 ng/ml. A dose range of the agonistic CP hIgG4 antibody is included for reference.
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hIgG4-GNG treated cultures (Figure 4A). All anti-CD40-GNG
targeting constructs gave similar CD4+ T cell GNG-speciﬁc
responses, except anti-CD40 11B6-CD40L-GNG elicited greater
GNG-speciﬁc responses at the lowest tested (0.001 nM or 1 pM)
dose consistently in two donors tested, although these were not
statistically signiﬁcant (Figure 4A and Supplemental Figure 2A).
In this donor, all anti-CD40-GNG targeting constructs elicited
CD8+ T cell responses speciﬁc to epitopes, especially within Nef,
while such cells were minimally represented in antigen nonstimulated or non-targeting hIgG4-GNG treated cultures
(Figure 4B). The most robust expansion of Nef-speciﬁc CD8+ T
cells was observed in cultures treated with 1 and 0.1 nM of the
highly activating anti-CD40 11B6-CD40L-GNG and anti-CD40
11B6-GNG + sCD40L constructs (Figure 4B and Supplemental
Figure 2B).
The improved antigen-speciﬁc CD8 + T cell response
associated with concomitant HIV-1 antigen delivery and
activation via CD40 we observed above with the GNG model
antigen suggested the possibility of a similar beneﬁt for CD40
targeting of the concatenated HIV5pep antigen cassette that is
well advanced towards clinical development (7, 21). HIV5pep
was designed to incorporate relatively conserved CD4+ and
CD8+ T cell epitopes across multiple HLA haplotypes from the
HIV-1 Gag, Nef, and Pol regions within ﬁve peptides. We
compared via in vitro PBMC expansion cultures various
formats of anti-CD40 11B6-CD40L-HIV5pep prototype

vaccines compared to the anti-CD40 12E12-HIV5pep Gen 2
vaccine (14). In the Gen 1 format, the ﬁve HIV-1 peptide regions
intercalated with glycosylated ﬂexible linkers are grafted to the
mAb H chain C-termini, and this is compatible with adding
CD40L to the available L chain C-termini. In the Gen 2 format,
the same long peptides and linkers are used, but two are now
grafted to the L chain C-termini. By conﬁguring the same 2 + 3
peptides and linkers on separate mAb H chains using knob-inhole (KIH) technology (23), highly activating anti-CD40 11B6CD40L-HIV5pep KIH was also available (Figure 2B). Previous
studies demonstrated that the Gen 1 and Gen 2 formats yield
identical in vitro HIV-1 antigen-speciﬁc T cell responses (14).
The Gen 1 and Gen 2 versions of the HIV5pep vaccine product
were unsuitable for Good Manufacturing Practice (GMP) scaleup due to fragmentation and aggregation issues that were not
evident at the research scale; the KIH Gen 3 product was
developed to circumvent these problems and is now in
GMP production.
We compared in vitro T cell responses to anti-CD40 12E12HIV5pep Gen 2 to the highly activating anti-CD40 11B6CD40L-HIV5pep Gen 1, and both vaccines elicited CD4+ T
cell responses speciﬁc to epitopes with the Gag17, Gag253,
Nef66, and Pol325 long peptide regions, as well as CD8+ T cell
responses within the Gag17 and Gag253 regions in the illustrated
donor (Figure 5). However, the highly activating anti-CD40 11B6CD40L-HIV5pep vaccine preferentially expanded the dominant

A

B

FIGURE 4 | Expansion by CD40-targeted GNG antigen of HIV-1-speciﬁc T cells in HIV-1-infected donor PBMC cultures. HIV-1+ donor PBMCs were cultured with a
dose range of anti-CD40-GNG fusion proteins with and without a low dose of sCD40L (100 ng/ml; 6 nM) and IL-2 for 9 days, followed by stimulation with peptides
for pools HIV-1 Gag p17, Nef, and Gag p24 for 6 h, then analyzed by ICS. The data show the percentage at the end of the culture of antigen-speciﬁc (A) CD4+ and
(B) CD8+ T cells producing IFNg + TNFa in response to peptide stimulation. Similar data were obtained in a replicated experiment (Supplemental Figure 2).
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Gag253-speciﬁc CD8+ T cell response, while the same CD4+ T cell
responses to Gag17, Gag253, Nef66 were elicited, but to a lesser
abundance (Figure 5B). Comparative in vitro T cell expansion
studies with anti-CD40-HIV5pep versus anti-CD40-CD40LHIV5pep constructs were replicated in three other HIV-1+
donors and are collated (Figure 6). Overall, T cell responses
were highly correlated between the vaccine pairs (Pearson’s test
0.85 for CD8+ and 0.7 for CD4+) indicating the vaccines presented
a similar array of epitopes for activating populations of antigenspeciﬁc T cells. However, the HIV-1-speciﬁc CD8+ T cell
responses were substantially (7.2X) more robust with the highly
activating anti-CD40-CD40L-HIV5pep vaccines (Figure 6A). In
contrast, the HIV-1-speciﬁc CD4+ T cell responses were similar or
slightly depressed (0.7X) with the highly activating anti-CD40CD40L-HIV5pep vaccines compared to anti-CD40-HIV5pep
(Figure 6B), likely reﬂecting the increased dominance of
antigen-speciﬁc CD8+ T cells in these cultures.
To extend our observations with HIV-1 donor PBMCs and to
further validate the importance of our vaccine platform
technology, we compared the ability of anti-CD40-CD40L to
target Inﬂuenza matrix 1 (Flu M1) protein and expand Flu M1speciﬁc memory T cells. PBMCs obtained by apheresis of
Normal Donor (ND) (All Cells, CA. ID:11588) were cultured
with dose ranges of Cohesin-Flu M1 alone (Flu M1) or in
complex with three different CD40-targeting antibody vehicles.
We have previously described a convenient method for noncovalent assembly of anti-DC antibodies and antigens using a
bacterial Dockerin (Doc) domain fused to the antibody heavy

chain C-terminus, and antigen such as Flu M1 fused to a Cohesin
(Coh) counter-domain (6). After an expansion culture period of
10 days, cells were harvested and restimulated with three pools
(clusters) of overlapping 15 mer peptides covering the entire Flu
M1 protein, then analyzed by ICS for peptide-elicited production
of intracellular IFNg and TNFa. As represented by the donor
shown in Figure 7 and statistically veriﬁed by four replicated
experiments, compared to Flu M1 alone, anti-CD40-Flu M1
complexes efﬁciently expanded CD8+ T cells speciﬁc to cluster 1,
with anti-CD40 11B6-CD40L showing a signiﬁcance advantage
at the 50 pM dose (p=0.018) (Figures 7A, C). Anti-CD40 11B6CD40L was more potent at the low concentrations tested (10 and
50 pM) compared to the other anti-CD40 antibodies, with a
signiﬁcant difference at 50 pM compared to anti-CD40 11B6
(p=0.035). In these same cultures, anti-CD40 11B6 and antiCD40 12E12 vehicles were similarly potent at expanding Flu M1speciﬁc CD4+ T cells to cluster 2 and 3 peptides, but these
responses were less robust with anti-CD40 11B6-CD40L
targeting (Figures 7B, C), likely due to the dominant
expansion of Flu M1-speciﬁc CD8+ T cells in these cultures.
All the three anti-CD40 targeting agents at the higher 50 pM
dose gave reduced or equal Flu M1-speciﬁc CD4+ T cell
expansion compared to Flu M1 alone (Figures 7B, C), but this
effect was not observed at the lower 10 pM dose or with Flu M1speciﬁc CD8+ T cell expansion (Figures 7A, C). Repeated
experiments with this donor conﬁrmed these results
(Figure 7C). These data, together with what we observed with
GNG and HIV5pep as antigens, demonstrate the high potency of

A

B

FIGURE 5 | CD40-targeted HIV5pep antigens with and without fused CD40L tested via in vitro expansion of HIV-1-speciﬁc T cells in HIV-1-infected donor PBMC
cultures. HIV-1+ donor 1 PBMCs were cultured for 9 days with IL-2 and anti-CD40 HIV5pep fusion proteins (1 nM), followed by stimulation with long peptides
speciﬁc for each of the ﬁve HIV-1 Gag, Nef, and Pol regions for 6 h with Golgi Stop + BFA, then analyzed by ICS. This is IHC data from one experiment with two of
the four indicated proteins tested on one of the donors shown in Figure 6. PSApep and sol indicate, respectively, non-relevant peptide and solvent only negative
controls, and PMA represents polyclonal stimulation by Phorbol 12-Myristate 13-Acetate and Ionomycin. Minimal responses to speciﬁc peptides were observed in
cultures expanded without vaccine stimulation (not shown) or with hIgG4-HIV5pep non-targeting control protein (7). (A) shows responses elicited by anti-CD40
12E12 HIV5pep Gen 2, and (B) shows responses elicited by anti-CD40 11B6-CD40L-HIV5pep Gen 1. Previous data show that Gen 1 versus Gen 2 HIV5pep
conﬁguration on anti-CD40 12E12 elicit identical ranges and extent of responses in similar experiments (14). Supplemental Figure 3 shows similar data for antiCD40 12E12-HIV5pep Gen3 versus anti-CD40 11B6-CD40L-HIV5pep Gen3 responses in Donor 3 as a more direct comparison with matching Gen3 formats.
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FIGURE 6 | Anti-CD40-CD40L targeted HIV5pep antigens preferentially expand many HIV-1-speciﬁc CD8+ T cell responses in HIV-1-infected donor PBMC cultures.
HIV-1+ donor PBMCs were cultured for 9 days with IL-2 and anti-CD40 HIV5pep fusion proteins (1 nM; 2 nM for KIH proteins), followed by stimulation with long
peptides speciﬁc for each of the ﬁve HIV-1 Gag, Nef, and Pol regions for 6 h with BFA, then analyzed by ICS. This is collated data from experiments with each of the
indicated protein pairs tested on four donors. Each point represents the % value for IFNg+ + TNFa+ HIV5pep-speciﬁc CD8+ [panel (A), black ﬁlled squares] or CD4+
[(B), gray circles] T cells for each response speciﬁc to each long peptide elicited in each donor comparing anti-CD40 11B6-CD40L-HIV5pep KIH Gen 2 and antiCD40 11B6-CD40L-HIV5pep Gen 1 (Y axis) to anti-CD40 12E12-HIV5pep KIH Gen 2 and anti-CD40 12E12-HIV5pep Gen 2 (X axis). The fold difference between the
antigen-speciﬁc CD8+ T cell responses elicited by anti-CD40 11B6-CD40L versus anti-CD40 12E12 was on average 7.2X, with a minimum of 0.3X and a maximum
of 61X, calculated on 36 coupled values in which 30 had a greater response to anti-CD40 11B6-CD40L. For this calculation, the threshold was 0.5% response in at
least one of the coupled values. (B) Shows the whole dataset. The fold difference between the antigen-speciﬁc CD4+ T cell responses elicited by anti-CD40 11B6CD40L versus anti-CD40 12E12 was on average 0.7X, with a minimum of 0.15X and a maximum of 2.4X, calculated on 44 coupled values in which 34 had a greater
response to anti-CD40 12E12. For this calculation, the threshold was 0.5% in the response in both of the values in the couples.

the anti-CD40 11B6-CD40L-antigen at the lower doses tested
and its improved efﬁcacy to preferentially expand CD8+ T cells
compared to anti-CD40 12E12-antigen.

11B6-CD40L-mediated antigen delivery to DCs can prolong antigen
presentation on MHC I, potentially explaining the observed
increased CD8+ T cell responses to anti-CD40 11B6-CD40L delivery.

Anti-CD40 11B6-CD40L-Melanoma gp100
Antigen Targeted to MDDCs Presents the
Immune-Dominant Class I Peptide 209-217
More Efﬁciently Than Anti-CD40Melanoma Antigen Fusions Without
Linked CD40L

Anti-CD40 11B6-CD40L-Antigen Vaccine
Platform Augment Adjuvant-Free In Vivo
Immune Responses in Mouse Models
To test the potential of anti-CD40 11B6-CD40L-antigen constructs
for increasing vaccine efﬁcacy in the absence of co-administered
adjuvant, human CD40 transgenic mice were vaccinated with
anti-CD40 11B6 hIgG4 delivery vehicles, with and without fused
CD40L, coupled to HIV-1 Env gp140. Vaccination with anti-CD40
11B6-CD40L directly fused to gp140 was compared to vaccination
with anti-CD40 11B6-CD40L non-covalently coupled to gp140 via
a Dockerin-Cohesin interaction (6), to anti-CD40 11B6 noncovalently coupled to gp140. Cohesin-gp140 was used as the
non-targeted control (Figure 9A). Both anti-CD40 11B6-CD40L
non-covalently coupled to gp140 and anti-CD40 11B6-CD40L
directly fused to gp140 elicited serum anti-gp140 IgG titers that
were detected as early as 13 days after a single vaccination
(Figure 9B, left panel). Responses to these anti-CD40 11B6CD40L-based vaccines increased to similar extents when
monitored 13 days after each of two subsequent vaccinations
administered at 2-week intervals (day 14 and day 21) after the
initial D0 vaccination. These responses were signiﬁcantly increased
compared to the group immunized with the non-targeted gp140
after the third vaccination (p<0.05) (Figure 9B, right panel) where
non-targeted control Cohesin-gp140 failed to elicit any detectable

To further investigate the improved CD8+ responses, we used the
1A9 mAb (15) to detect processing and presentation on MDDCs of
the melanoma gp100 Class I peptide gp100 209-217 in the context of
cell surface HLA-A2. Indeed, the size of the CD8+ T cell responses is
known to correlate with the duration of the antigen presentation
(24). To deliver the peptide via DC-targeting, anti-human CD40
IgG4 mAbs with and without directly linked CD40L were fused via
the H chain C-terminus to two copies of the peptide interspersed
between ﬂexible linker sequences (7). These constructs at 50 nM
were incubated with MDDCs, and the cells were probed with the
labeled 1A9 mAb after 24, 48, and 72 h and analyzed by ﬂow
cytometry. In three independent experiments, compared to antiCD40 11B6-gp100 or anti-CD40 12E12-gp100-loaded MDDCs,
anti-CD40 11B6-CD40L-gp100-loaded MDDCs had greater and
more sustained speciﬁc cell surface reactivity to the 1A9 mAb,
which correlates with the observed increase in expression of
surface activation markers CD83 and CD86 (Figure 8 and
Supplemental Figure 1C). These results suggest that anti-CD40
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FIGURE 7 | Anti-CD40-CD40L-targeted Flu M1 antigen preferentially expands Flu M1-speciﬁc CD8+ T cell responses at low doses in normal donor PBMC cultures.
Normal donor PBMCs were cultured for 9 days with IL-2 and a dose range of anti-CD40 vehicles in complex with Flu M1 protein, followed by stimulation with Flu M1
peptide pools for 6 h with Golgi Stop and BFA, then analyzed for intracellular IFNg+ and TNFa+ by ICS. Results for one representative experiment for CD8+ T cells
stimulated with cluster 1 (A) and CD4+ T cells stimulated with cluster 2 (B) are shown. (C) shows repeated experiments with this donor treated with 0.05 and 0.01
nM of the different anti-CD40 vehicles in complex to Flu M1 protein or controls (n=4 for 0.01 nM and n=3 for 0.05 nM); data are represented as n – untreated cells.
In all cases anti-hCD40 11B6-CD40L gave more robust CD8+ T cell responses at these low concentrations (mean = 9.1% ± 2 at 0.05 nM and = 3.8% ± 4.4 at 0.01 nM)
than the other conditions (mean = 2.9% ± 2.4 at 0.05 nM and = 1.3% ± 0.6 at 0.01 nM). Previous studies [(6); Figure 5] have demonstrated that additional Coh-Flu M1
and hIgG4-Doc: Coh-Flu M1 non-targeting controls gave similar minimal responses compared to CD40-Doc: Coh-Flu M1. Supplemental Table 2 shows in detail each
Inﬂuenza Matrix 1 peptide used and how they are grouped into three clusters. * indicates a statistically signiﬁcant difference of P=0.01-0.05.

A well-established mouse model for T cell vaccine response
uses adoptively transferred CD4+ T cells from TCR I-Ea52-68
transgenic mice (25). We compared vaccination with anti-CD40
11B6 versus anti-CD40 11B6-CD40L for targeted delivery of Ea
antigen for evoking proliferation and activation of these adoptively
transferred cells (Figure 10A). In both cases, in response to a
single 1 µg dose of each construct, >80% of the adopted TEa CD4+
T cells proliferated over the 4 days period subsequent to
vaccination, indicating efﬁcient processing and presentation of
the antigen by both constructs (Figure 10B). However, a

anti-gp140 IgG responses even after three vaccinations despite
using a three-fold molar excess of gp140 compared to the CD40targeting vaccines. Vaccination responses following the same
administration and sampling schedule as above with anti-CD40
11B6 non-covalently linked to gp140 elicited serum anti-gp140 IgG
titers that were detected only after a second vaccination (Figure 9B,
D27 middle panel), and increased further after the third (day 21)
vaccination (Figure 9B, D34 right panel), but the titers were
substantially lower compared to the two anti-CD40 11B6CD40L-based vaccines.

Frontiers in Immunology | www.frontiersin.org

12

January 2022 | Volume 12 | Article 786144

Ceglia et al.

Intrinsic Adjuvant Vaccines

A

B

FIGURE 8 | Anti-CD40-CD40L-targeted melanoma gp100 antigen is efﬁciently presented on MDDC HLA-A2. Normal donor MDDCs were treated with 50 nM antiCD40 or control hIgG4 antibodies fused to a dominant Class I gp100 peptide. Cultures were harvested at 24, 48, and 72 h and probed with ﬂuorescently tagged
1A9 mAb to detect surface gp100 peptide/HLA-A2 complex via ﬂow cytometry analysis. (A) The panels show frequency versus ﬂuorescence intensity plots of
MDDCs treated with either the indicated anti-CD40-gp100 constructs (black outline), or control hIgG4-gp100 (gray areas). The data are one representative of three
independent experiments. (B) Total ﬂuorescence of each anti-CD40-gp100-treated population was calculated and compared to the hIgG4-gp100-treated cells,
which was set at 100%. Averaged over the three experiments and over the three time points anti-CD40 11B6-CD40L-gp100 gave a mean value of 155 ± 35; antiCD40 11B6-gp100 mean = 107 ± 14; anti-CD40 12E12-gp100 mean = 107 ± 19. The overall values for anti-CD40 11B6-CD40L-gp100 were signiﬁcantly greater
compared to 11B6-gp100 (p = 0.0032), 12E12-gp100 (p = 0.0034), and hIgG4-gp100 (p = 0.0015). ** indicates a statistically signiﬁcant difference of P=0.001-0.01.

signiﬁcantly higher proportion of the proliferating TEa CD4+ T
cells were primed for IFNg production by the anti-CD40 11B6CD40L-TEa vaccine (18± versus 5±%, p<0.0001, Figure 10C).
To further explore the possible advantage in efﬁcacy for
raising cellular immunity by targeting antigen via anti-CD40

Frontiers in Immunology | www.frontiersin.org

11B6-CD40L, we established EO771 mammary adenocarcinoma
tumors [derived from a spontaneous mammary tumor in a
female C57BL/6 mouse (26)] in human CD40 transgenic
female mice. These tumors express Cyclin D1, a tumorassociated antigen common in breast cancers (27). At days 7,
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FIGURE 9 | CD40-targeted HIV-1 gp140 antigen with fused CD40L elicits superior gp140-speciﬁc serum IgG responses in human CD40 transgenic mice. (A) Human
CD40 homozygous transgenic mice were vaccinated via intraperitoneal injection with (Group 1) anti-CD40 11B6-CD40L directly fused to HIV-1 gp140, (Group 2) antiCD40 11B6-CD40L-Dockerin + Cohesin-gp140, (Group 3) anti-CD40 11B6-Dockerin + Cohesin gp140, or (Group 4) Cohesin-gp140. Dose was normalized to be the
molar equivalent of 1 mg of the Group 2 vaccine, except for the non-targeting control Group 3 (2 mg or ≅3 molar equivalents). Vaccination was at Day 1, Day 14, and Day
21 with small blood draws taken at Day 13 (D13), Day 27 (D27), and Day 34 (D34). (B) The graphs show serial dilutions of sera analyzed for anti-gp140 IgG reactivity by
ELISA as described in (16) except that anti-mouse IgG-HRP reagent was the detecting reagent. Group sizes were G1, n=3 and G2-4, n=4. Directional error bars are S.E.
of the mean. * indicates a statistically signiﬁcant difference of P=0.01-0.05.

primates have shown the beneﬁt for both humoral and cellular
immune responses of co-administering anti-CD40 12E12-based
vaccines with poly ICLC (Hiltonol™), a TLR3-stimulating
adjuvant (9–11). Early-phase clinical trials have shown that poly
ICLC is safe and well tolerated (29), but it is attractive to consider
potential beneﬁts of delivery of antigen to APCs concomitant with
activation of the same cells via a single vaccine product. The
mechanism of reduced CD40 activation by anti-CD40 12E12 via
antigen fusion is not known, but here we show that
hyperactivating anti-CD40 11B6-CD40L antibody fused to all
antigens we tested (i.e., HIV5pep, GNG, HPV E6/E7, Flu M1)
maintains strong CD40 agonist activity. Our previous study with
anti-CD40-CD40L fusion antibodies (13) revealed that this format
clusters surface CD40 on DC very effectively and is internalized
more rapidly, properties likely due to the tetravalent conﬁguration
that facilitates cross-linking and greatly stabilized CD40 off-rate.
Here we conﬁrmed that this decrease in off-rate was maintained in
the context of fused antigen.
Tests with PBMC cultures using three different antigen adducts
(Gag p24-Nef-Gag p17, HIV5pep, and Flu M1) demonstrated
superiority of anti-CD40-CD40L-based targeting for eliciting
expansion of antigen-speciﬁc CD8+ T cells, and increased
efﬁcacy at very low doses for eliciting antigen-speciﬁc CD4+ T
cells. For example, in HIV-1+ donors comparing highly activating

17, and 24, mice implanted with tumor at day 0 were vaccinated
with anti-CD40 11B6-CD40L-Doc, anti-CD40 11B6-Doc, IgG4CD40L-Doc, and non-targeting IgG4-Doc non-covalently linked
to human Coh-Cyclin D1 (Figure 11A). Only the anti-CD40
11B6-CD40L-Cyclin D1 group showed reduction in tumor
growth (Figure 11B), indicating the low impact of nontargeted antigen, or antigen targeted to CD40 without strong
CD40 activation potential, versus the signiﬁcantly improved
ability of the anti-CD40-CD40L vehicle to partially control
tumor growth.

DISCUSSION
Discovering that linking CD40L to select agonistic anti-CD40
antibodies confers superagonist properties (13) opened an avenue
to exploring potential advantages for CD40-targeting vaccines that
hyperactivate CD40. Five CD40-targeting vaccines are currently in
clinical development, i.e., anti-CD40-HPV16 E6/E7 (9), antiCD40-HIV-1 Env gp140 (10), anti-CD40-HIV5pep (14, 21), and
anti-CD40 fused to SARS-CoV-2 proteins (28). Although based
on the agonistic anti-CD40 12E12 antibody, these antigen fusions
have relatively low CD40 agonist activity. In vivo studies in human
CD40 transgenic mice, humanized mice, and non-human
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FIGURE 10 | Anti-CD40 11B6-CD40L-targeted Ea antigen elicits superior proinﬂammatory cytokine production in Ea-speciﬁc CD4+ T cells in human CD40
transgenic mice. (A) Human CD40 homozygous transgenic mice were adoptively transferred i.v. with CTV-labeled Ea CD4+ T cells and 1 day later, immunized with
anti-CD40 11B6-Doc complexed with Cohesin-Ea or anti-CD40 11B6-CD40L-Doc complexed with Cohesin-Ea (1 mg). Four days later cells from the skin draining
lymph node were examined by ﬂow cytometry for proliferation (B) and activation (C) of the Ea cells. To determine the activation status, some cells were stimulated
with PMA/Ionomycin and then stained for intracellular IFNg. Each dot represents a separate mouse. Data from three independent experiments were pooled. ** and
**** indicate statistically signiﬁcant differences as deﬁned in Materials and Methods. ns indicates no signiﬁcant difference.

anti-CD40 11B6-CD40L versus non-activating anti-CD40 11B6 or
anti-CD40 12E12 antibodies fused to HIV-1 antigens revealed no
overall changes in the repertoire of expanded antigen-speciﬁc
memory T cells. However, the highly activating anti-CD40
11B6-CD40L-HIV5pep, anti-CD40 11B6-CD40L-GNG, or antiCD40 11B6-CD40L:Cohesin-Flu M1 vaccines were consistently
more effective in vitro at expanding antigen-speciﬁc CD8+ T cells.
The role of the CD40-CD40L pathway in inducing CD8+ T cell
activation into cytotoxic T cells has been extensively studied (30–
35). In particular, it has been shown that one way of activating
CD8+ T cells during the course of an infection involves interaction
between CD40L-expressing activated CD4+ T cells and the CD40expressing DCs, which then feeds back to increased activation of
the DCs, thus further stimulating nearby antigen-speciﬁc CD8+ T
cells (30). In our model we are immediately inducing this DC
superactivation through the combined action of CD40 binding via
the anti-CD40 mAbs and the engagement of CD40L directly fused
to the light chain of the antibodies. We have demonstrated that
this platform induces a stronger DC activation compared to antiCD40 mAbs or CD40L form acting alone (13), and this may
overcome the necessity to engage help from antigen-speciﬁc CD4+
T cells. An alternative model to account for preferential expansion
of antigen-speciﬁc CD8+ T cells observed in vitro involves the antiCD40-CD40L vaccine serving as a surrogate for direct interaction
between the CD40L-expressing CD4 + T cells and CD40expressing CD8+ T cells, by directly binding CD40-expressing
CD8+ T cells, playing a more direct role in their activation.
However, by knowing the two antibodies do not cross compete
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(13), we tested an equimolar dose of anti-CD40 11B6-CD40L as a
potential adjuvant added to cells cultured with anti-CD40 12E12Flu M1, and this did not increase the cluster 1 CD8+ T cell
response (data not shown). In some cases, there was a
commensurate reduction in the extent of antigen-speciﬁc CD4+
T cell expansion, although this could be simply due to competition
in the culture by the more aggressively expanding CD8+ T cells.
Importantly, by directly probing presentation of melanoma
gp100 Class I peptide gp100 209-217 in the context of cell surface
HLA-A2, we demonstrated that anti-CD40 11B6-CD40L
targeting of this antigen resulted in signiﬁcantly more
sustained presentation of this antigen on MDDCs than
delivery by anti-CD40 11B6 or anti-CD40 12E12 vehicles,
another characteristic that can induce a stronger CD8+ T cell
response. This suggests anti-CD40 11B6-CD40L targeting offers
further improvement of this important immune parameter over
what has already been documented for anti-CD40 12E12 delivery
versus targeting to other DC receptors (8). This more sustained
Class I antigen presentation may be a consequence of the more
efﬁcient internalization we observed with anti-CD40 11B6CD40L antibody compared to anti-CD40 11B6 or anti-CD40
12E12 antibodies (13).
The observed in vitro increases in efﬁcacy and potency for
eliciting, respectively, antigen-speciﬁc CD8+ and CD4+ T cell
responses raise the possibility that anti-CD40-CD40L-based
antigen fusions may have advantages when used in vivo. In
particular, the high agonist activity of this novel vaccine format
offers promise of efﬁcacious immune responses when used without
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FIGURE 11 | Anti-hCD40-CD40L treatment signiﬁcantly reduces tumor burden in a therapeutic setting. Seven days post-inoculation with TNBC EO771.LMB tumor
cells, human CD40 transgenic mice were randomized in different groups and vaccinated as indicated in (A) with 20 mg ant-CD40-CD40L vaccine or controls at days
7, 17, and 24. Tumor volumes were recorded by caliper measurements at the indicated time points and presented as mean ± SEM. (B) One representative
experiment out of six is shown. Mice where the tumor did not uptake were excluded from the data. Between three and six mice were in each group. Statistics were
calculated starting from D14 post tumor injection and statistical signiﬁcance was P < 0.05, indicated by *.

The concept of vaccination via co-administrating activation of
CD40 concomitantly with antigen delivery has also been
approached using multimeric forms of CD40L fused to antigen,
and in vivo mouse studies have shown promising efﬁcacy for
antibody (36, 37) and protective T cell responses (38–40).
Progression of highly DC activating anti-CD40-CD40L-based
vaccines with a high potential for adjuvant-free administration
towards future clinical application will require additional such
extended in vivo studies, including dose ranging, for comparing
them to the current CD40-targeting vaccine + poly IC
formulations in clinically more relevant humanized mouse and
non-human primate studies designed to demonstrate protective
immunity or viral control. Our studies using an array of antigen
settings point to likely advantages in skewing in vivo immunity
towards cytotoxic cellular immunity, as well as overall potency at
low dosage, of vaccines based on this platform technology.

co-administered adjuvant. The anti-human CD40 antibodies in
our study do not cross-react with mouse CD40; thus, non-human
primates or humanized mice are the most relevant in vivo models
to test the efﬁcacy of CD40-targeting vaccines based on highly
activating anti-CD40-CD40L-antigens. As a prelude to such
studies, we used human CD40 transgenic mice to probe possible
advantages of anti-CD40 11B6-CD40L vaccines for inducing
antigen-speciﬁc immune responses in the absence of adjuvant.
In three adjuvant-free in vivo studies, we demonstrated that (i)
anti-CD40 11B6-CD40L-HIV-1 Env gp140 elicited more potent
CD40-targeting dependent anti-Env gp140 antibody responses
than anti-CD40 11B6-HIV-1 Env gp140; (ii) anti-CD40 11B6CD40L-Ea and anti-CD40 11B6-Ea were equally effective in
driving Ea-speciﬁc CD4+ T cell proliferation, but the anti-CD40
11B6-CD40L-Ea vaccine elicited more potent Ea-speciﬁc CD4+ T
cell IFNg production; and (iii) anti-CD40 11B6-CD40L-Cyclin D1
vaccination inhibited the growth of transplanted Cyclin D1+
EO771 mammary adenocarcinoma tumors, while anti-CD40
11B6-Cyclin D1 and control IgG4-Cyclin D1 vaccines had no
effect. These pilot studies clearly suggest potential beneﬁts of
adjuvant-free DC-targeting vaccines based on highly activating
anti-CD40-CD40L vehicles, providing impetus for further in
vivo studies.
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